Synthase Biotech
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Synthase Biotech Ltd is a Hamilton, New Zealand-based biotechnology startup founded in 2015, commercialising a novel enzyme platform. Its flagship product Aloxsyn, a plant-derived enzyme with extraordinary specificity against toxic lipid peroxides, prevents and repairs oxidative damage to cell membranes - a key process in cellular damage and ageing. Starting in the livestock fertility space (frozen bull semen and cattle embryos for AI/IVF), it has run large-scale US trials with statistically significant results; it is backed by Matu Group and holds IP with pending patents. No failure has been reported; it remains active.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
Synthase Biotech Ltd was founded in Hamilton, New Zealand, to commercialise its Aloxsyn enzyme platform.
- Funding and profile
By 2019 the company had taken in around $3.4 million in funding and contributions; its seed round in January 2019 was led by Matu Group, and large-scale US livestock trials later showed statistically significant results.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.